ARCHIVES

FDA seeks support for reorganization of cancer programs, but debate continues.

This article is from The Cancer Letter archive.

Vol. 30 No. 28 | July 9, 2004

Download PDF Visit The Full Archive

Related Articles

Natcher: Multiple Year Funding Would Not be Approved If Presented As Request For Reprogramming

March 22, 1985

Gene Expression Analyses Can Guide MDS Treatments

December 30, 2011

ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic.

April 9, 2010

Revlimid Also Demonstrates Response in Mantle Cell

July 29, 2011

Chemical Carcinogenesis

November 18, 1994

Bad News for EPO Products Brings FDA Scrutiny, Payment Curbs. FDA Issues Alert to Doctors.

February 23, 2007